David Hoang
Stock Analyst at Deutsche Bank
(3.60)
# 849
Out of 5,118 analysts
48
Total ratings
52.63%
Success rate
7.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics | Initiates: Buy | $103 | $76.38 | +34.85% | 1 | Dec 10, 2025 | |
| ALKS Alkermes | Maintains: Buy | $55 → $45 | $28.01 | +60.66% | 3 | Nov 13, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $65 → $280 | $304.58 | -8.07% | 2 | Oct 17, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Buy | $43 | $32.56 | +32.06% | 1 | Sep 26, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $54 → $36 | $37.91 | -5.04% | 4 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Sell | $6 → $12 | $21.82 | -45.00% | 10 | Aug 15, 2025 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Buy | $20 → $35 | $27.26 | +28.39% | 5 | May 21, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Buy | $67 | $44.33 | +51.14% | 3 | Feb 11, 2025 | |
| DNLI Denali Therapeutics | Initiates: Buy | $31 | $16.58 | +86.97% | 3 | Feb 11, 2025 | |
| BHVN Biohaven | Initiates: Buy | $65 | $11.54 | +463.26% | 1 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $176 | $150.68 | +16.80% | 4 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $21.55 | -44.32% | 1 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $150 → $158 | $143.64 | +10.00% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $2.00 | +250.00% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $5.69 | +181.20% | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $4.04 | +296.04% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $220 | $398.82 | -44.84% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $69.62 | +14.91% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 | $3.21 | -6.54% | 1 | Dec 7, 2022 |
Apogee Therapeutics
Dec 10, 2025
Initiates: Buy
Price Target: $103
Current: $76.38
Upside: +34.85%
Alkermes
Nov 13, 2025
Maintains: Buy
Price Target: $55 → $45
Current: $28.01
Upside: +60.66%
Praxis Precision Medicines
Oct 17, 2025
Maintains: Buy
Price Target: $65 → $280
Current: $304.58
Upside: -8.07%
Spyre Therapeutics
Sep 26, 2025
Initiates: Buy
Price Target: $43
Current: $32.56
Upside: +32.06%
Harmony Biosciences Holdings
Sep 25, 2025
Maintains: Buy
Price Target: $54 → $36
Current: $37.91
Upside: -5.04%
Sarepta Therapeutics
Aug 15, 2025
Maintains: Sell
Price Target: $6 → $12
Current: $21.82
Upside: -45.00%
ACADIA Pharmaceuticals
May 21, 2025
Upgrades: Buy
Price Target: $20 → $35
Current: $27.26
Upside: +28.39%
Xenon Pharmaceuticals
Feb 11, 2025
Initiates: Buy
Price Target: $67
Current: $44.33
Upside: +51.14%
Denali Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $31
Current: $16.58
Upside: +86.97%
Biohaven
Feb 11, 2025
Initiates: Buy
Price Target: $65
Current: $11.54
Upside: +463.26%
Feb 11, 2025
Initiates: Buy
Price Target: $176
Current: $150.68
Upside: +16.80%
Feb 11, 2025
Initiates: Buy
Price Target: $12
Current: $21.55
Upside: -44.32%
Aug 2, 2024
Maintains: Neutral
Price Target: $150 → $158
Current: $143.64
Upside: +10.00%
Jul 25, 2024
Initiates: Buy
Price Target: $7
Current: $2.00
Upside: +250.00%
Mar 15, 2024
Initiates: Buy
Price Target: $16
Current: $5.69
Upside: +181.20%
Mar 7, 2024
Initiates: Buy
Price Target: $16
Current: $4.04
Upside: +296.04%
Apr 26, 2023
Initiates: Neutral
Price Target: $220
Current: $398.82
Upside: -44.84%
Apr 26, 2023
Initiates: Outperform
Price Target: $80
Current: $69.62
Upside: +14.91%
Dec 7, 2022
Downgrades: Neutral
Price Target: $3
Current: $3.21
Upside: -6.54%